Eight months after bucking the trend by filing to go public in a very unhospitable market, Woburn, MA-based BioTrove has evidently thought better of things. The MIT spinoff, which is developing tools for genomic analysis and drug discovery, today pulled the planned offering, which was to have been worth up to $75 million. BioTrove might undertake a private offiering, the company noted in its new filing with the SEC.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
